NEW YORK, Sept. 08, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zebra Technologies Corporation (NASDAQ:ZBRA) from March 17, 2015 through May 9, 2016, inclusive (the “Class Period”) of the important September 25, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Zebra investors under the federal securities laws.
To join the Zebra class action, go to http://rosenlegal.com/cases-1171.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
The complaint alleges that during the Class Period, defendants issued materially false and misleading statements and/or failed to disclose adverse information regarding Zebra’s business, prospects and financial results. Specifically, defendants failed to disclose that Zebra had understated its income taxes through the end of 2015, underaccrued certain 2015 estimates, in particular with respect to its sales commission plan, and overstated the net realizable value of trade receivables acquired in connection with the Company’s acquisition of Motorola’s Enterprise division. Zebra also failed to disclose the impact of material weaknesses identified in its internal controls and procedures over financial reporting and disclosure, which caused the misstatements and rendered the Company’s financial guidance for 2015 and the first and second quarters of 2016 materially false and misleading. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 25, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1171.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Italy Fines Apple €98.6 Million Over App Store Dominance
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 



